Format

Send to

Choose Destination
Urol Case Rep. 2019 Oct 15;28:101048. doi: 10.1016/j.eucr.2019.101048. eCollection 2020 Jan.

Complete response to nivolumab for metastatic renal cell carcinoma on hemodialysis patient; a case report.

Author information

1
Department of Urology, Iwate Medical University, Japan.
2
Division of Urology, Noshiro Kosei Medical Center, Japan.

Abstract

A 73-year-old-male patient with hypertension and grade 3B chronic kidney disease underwent radical nephrectomy in the year 2000. As the renal function gradually worsened, the patient was started on hemodialysis in 2003. Eleven years after nephrectomy, the metastases were pointed out. The patient received sunitinib as first-line therapy. Thereafter, as the metastatic lesions became larger, we initiated nivolumab therapy (3 mg/m2 every 2 weeks). After 52 weeks, the metastatic lesions continued showing complete response (CR). No adverse effects were observed during nivolumab treatment.

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center